Literature DB >> 26278870

Role of Endoscopic Third Ventriculostomy in the Management of Myelomeningocele-Related Hydrocephalus: A Retrospective Study in a Single French Institution.

Pierre-Aurelien Beuriat1, Alexandru Szathmari1, Blandine Grassiot1, Franck Plaisant2, Christophe Rousselle1, Carmine Mottolese3.   

Abstract

INTRODUCTION: Treatment of hydrocephalus related to myelomeningocele (MM) is debated. Endoscopic third ventriculostomy (ETV) has been proposed with contrasting results. We report our experience in the management of hydrocephalus related to MM and the advantages of ETV.
MATERIAL AND METHODS: From 1994 to 2012, we treated 97 patients with MM. Seventy patients developed a hydrocephalus needing a surgical treatment. Three types of procedures were used: ETV with concomitant choroid plexus coagulation (CPC), ETV with concomitant ventriculoperitoneal shunt (VPS), or VPS.
RESULTS: Thirty-two patients had an ETV with CPC, 20 patients had an ETV and a concomitant VPS, and 18 patients had a VPS. No perioperative complications were reported. Fifty-two patients underwent an ETV. The overall success rate of ETV was approximately 70%. DISCUSSION: VPS in patients with MM leads to complications. Two common arguments are reported against ETV. The first is the variability of the anatomy of the ventricle leading to possible operative complications. The second is the immaturity of the Pacchioni granulations. For us, the modified anatomy does not prevent performing ETV. Regarding the issue of cerebrospinal fluid absorption in failed ETV, the adjunction of a shunt helps to control hydrocephalus until the maturation of the Pacchioni system.
CONCLUSIONS: Preoperative imaging helps the surgical decision to predict in which patients the ETV can be realized without risks. ETV in patients with MM is a secure procedure with low rates of failure and no mortality, and it reduces the rate of shunt implantation.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Endoscopic third ventriculostomy; Hydrocephalus; Myelomeningocele; Outcome; Ventriculoperitoneal shunt

Mesh:

Year:  2015        PMID: 26278870     DOI: 10.1016/j.wneu.2015.07.071

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

Review 1.  Endoscopic third ventriculostomy versus shunt for pediatric hydrocephalus: a systematic literature review and meta-analysis.

Authors:  Pavlos Texakalidis; Muhibullah S Tora; Jeremy S Wetzel; Joshua J Chern
Journal:  Childs Nerv Syst       Date:  2019-05-25       Impact factor: 1.475

2.  First 60 fetal in-utero myelomeningocele repairs at Saint Louis Fetal Care Institute in the post-MOMS trial era: hydrocephalus treatment outcomes (endoscopic third ventriculostomy versus ventriculo-peritoneal shunt).

Authors:  Samer K Elbabaa; Anne M Gildehaus; Matthew J Pierson; J Andrew Albers; Emanuel J Vlastos
Journal:  Childs Nerv Syst       Date:  2017-05-03       Impact factor: 1.475

3.  Endoscopic third ventriculostomy versus ventriculoperitoneal shunt in pediatric and adult population: a systematic review and meta-analysis.

Authors:  Apurva Pande; Nayan Lamba; Marco Mammi; Paulos Gebrehiwet; Alyssa Trenary; Joanne Doucette; Stefania Papatheodorou; Adomas Bunevicius; Timothy R Smith; Rania A Mekary
Journal:  Neurosurg Rev       Date:  2020-05-31       Impact factor: 3.042

4.  Low level myelomeningoceles: do they need prenatal surgery?

Authors:  Pierre-Aurelien Beuriat; Isabelle Poirot; Frederic Hameury; Delphine Demede; Kieron J Sweeney; Alexandru Szathmari; Federico Di Rocco; Carmine Mottolese
Journal:  Childs Nerv Syst       Date:  2019-03-27       Impact factor: 1.475

Review 5.  Efficacy and safety of endoscopic third ventriculostomy and choroid plexus cauterization for infantile hydrocephalus: a systematic review and meta-analysis.

Authors:  Alexander G Weil; Harrison Westwick; Shelly Wang; Naif M Alotaibi; Lior Elkaim; George M Ibrahim; Anthony C Wang; Rojine T Ariani; Louis Crevier; Bethany Myers; Aria Fallah
Journal:  Childs Nerv Syst       Date:  2016-09-09       Impact factor: 1.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.